Modulation of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2)-mediated immune response

NZ835440APending Publication Date: 2026-07-31REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
NZ835440
Authority / Receiving Office
NZ · NZ
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-04-07
Filing Date
2021-07-23
Publication Date
2026-07-31

Smart Images

  • Figure 00000175_0000
    Figure 00000175_0000
  • Figure 00000183_0000
    Figure 00000183_0000
  • Figure 00000184_0000
    Figure 00000184_0000
Patent Text Reader

Abstract

The present disclosure provides methods of treating subjects having an immune disorder by administering a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor to the subject, and optionally an Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) agonist or inhibitor and / or an HLA-Aw19 inhibitor, and also provides methods of identifying subjects having an increased risk for developing an MHC-I-opathy.
Need to check novelty before this filing date? Find Prior Art